GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Tax Provision

Accelerated Pharma (Accelerated Pharma) Tax Provision : $0.00 Mil (TTM As of Mar. 2017)


View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Tax Provision?

Accelerated Pharma's tax provision for the three months ended in Mar. 2017 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2017 was $0.00 Mil.


Accelerated Pharma Tax Provision Historical Data

The historical data trend for Accelerated Pharma's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Tax Provision Chart

Accelerated Pharma Annual Data
Trend Dec14 Dec15 Dec16
Tax Provision
- - -

Accelerated Pharma Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Tax Provision Get a 7-Day Free Trial - - - - -

Accelerated Pharma Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accelerated Pharma (Accelerated Pharma) Business Description

Traded in Other Exchanges
N/A
Address
Website
Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines